HOME >> BIOLOGY >> NEWS
Common anti-depressants similarly safe and effective for treating postpartum depression

ssion, the investigators evaluated the women for remission of depressive symptoms at four, eight and 24 weeks. The latter evaluation point included only women who had responded after eight weeks. Of the original 109 participants, 95 provided response data at four weeks, 83 provided data at eight weeks, and 29 completed between 20 and 24 weeks of the study.

The proportion of women who responded with a reduction in depressive symptoms, and those who remitted, having few depressive symptoms consistent with wellness, did not significantly differ between the two drugs at any of the study's time points. By week four, 46 percent of the participants taking sertraline had responded and 27 percent remitted, while 56 percent of those taking nortriptyline responded and 30 percent remitted. At eight weeks, 56 percent of the participants on sertraline had a reduction of symptoms and 46 percent had no symptoms, while the participants taking nortriptyline had 69 percent respond and 48 percent remit. Of the 29 participants who remained in the study until 20-24 weeks, 93 percent taking sertraline responded and 73 percent remitted, while 100 percent taking nortriptyline responded and 79 percent remitted. None of these differences were significant by statistical analyses.

Additionally, researchers found that psychosocial functioning improved similarly with use of both drugs. Neither drug proved to be superior to the other in treating aggressive obsessional thoughts. Side-effect burdens were the same, although side effects differed between the drugs. Overall, the majority of women responded to both of the drugs within two to four weeks.

"Conventional wisdom says that it can take six to eight weeks for a person to respond to an antidepressant. Several weeks is simply too long to wait for a response in postpartum depression," said Dr. Wisner. "It's encouraging to see that these women responded quickly and well to the study medications and that now we have
'"/>

Contact: Jocelyn Uhl Duffy
uhljh@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
15-Aug-2006


Page: 1 2 3

Related biology news :

1. Common environmental chemicals in diet affect fetal ovarian development
2. Common cancer gene sends death order to tiny killer
3. Common treatment for methamphetamine overdose may damage brain cells
4. Common genetic variation is linked to substantial risk for heart attack
5. Common fungicide causes long-term changes in mating behavior
6. DNA ends: Common tool, different job
7. Common gene version optimizes thinking -- but with a possible downside
8. Common mechanisms for viral DNA replication
9. Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia
10. Common cause of heart disease, diabetes may be treatable with malaria drug
11. Commonplace sugar compound silences seizures

Post Your Comments:
(Date:7/24/2014)... is available in German . ... 300 million asthma sufferers worldwide, a further 600 million ... of the global population contending with allergic rhinitis (allergic ... also affect other organs and parts of the body ... intestine (in the form of inflammatory bowel diseases such ...
(Date:7/24/2014)... is available in German . ... recognize and respond to threats to health, and to ... understanding of the mechanism underlying immunologic memory, however, has ... converged to support the hypothesis that the persistence of ... with stem-cell-like potential. Until now, there was no conclusive ...
(Date:7/23/2014)... of identical twins has found that early reading skill ... the journal Child Development , was conducted by ... London. , "Since reading is an ability that can ... according to Stuart J. Ritchie, research fellow in psychology ... "Early remediation of reading problems might aid not only ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3Stronger early reading skills predict higher intelligence later 2
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
Cached News: